Purdue Pharma LP:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Purdue Pharma LP - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3323
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Purdue Pharma LP (Purdue) is a privately held, US-based pharmaceutical company which develops pharmacologic therapies for the treatment and management of pain. The company undertakes the research, development, manufacture and marketing of prescription medicines and over-the-counter (OTC) medicines and related healthcare products. Its major product categories include prescription opioids, sedatives (for sleep disorders), laxatives, antiseptics and dietary supplements. The company also conducts clinical studies on new investigational drugs and pharmaceuticals on the market. The company operates three facilities in North Carolina and New Jersey. It is a member of MundiPharma International Limited’s network of independent associated companies. Purdue is headquartered in Stamford, Connecticut, the US.

Purdue Pharma LP – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Purdue Pharma LP, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Purdue Pharma Acquires Rights to VM-902A from VM Pharma 12
Venture Financing 13
Kolltan Pharma Raises US$60 Million In Series D Financing 13
Partnerships 15
Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 15
University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 16
University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 17
Purdue Pharma to Form Joint Venture with AnaBios 18
Eisai Enters into Agreement with Purdue Pharma 19
Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 20
ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 21
Licensing Agreements 22
Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 22
Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 23
Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 24
Purdue Pharma Enters into Licensing Agreement with Exicure 25
Purdue Pharma Enters into Licensing agreement with AnaBios 26
Purdue Pharma Enters Into Licensing Agreement With Medical Developments 27
Helsinn Signs Licensing Agreement with Purdue Pharma Canada 28
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 29
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 30
Purdue Pharma LP – Key Competitors 31
Purdue Pharma LP – Key Employees 32
Purdue Pharma LP – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Corporate Communications 34
Jul 24, 2018: Purdue Pharma announces leadership changes 34
Mar 01, 2018: Purdue Pharma L.P. Names Dr. Marcelo Bigal as Chief Medical Officer 36
Jun 22, 2017: Dr. Craig Landau Appointed President and CEO Purdue Pharma L.P. 37
Legal and Regulatory 38
Aug 02, 2018: Orland Fire joins 13 municipalities in class action suit to block Opioid addiction 38
Jun 12, 2018: Mass. Sues Purdue Pharma over 670 residents who fatally overdosed on opioids 39
Jun 08, 2018: Tenn. Attorney General Seeks to Make State’s Complaint against Purdue Pharma Public 40
Feb 06, 2018: Beasley Allen files opioid lawsuit on behalf of the State of Alabama 41
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 42
Government and Public Interest 43
Feb 09, 2018: Purdue Pharma Issues Statement on Opioid Promotion 43
Jan 31, 2018: Purdue Pharma L.P. Awards Grants to Further Research on the Assessment of Chronic Pain 44
Product News 45
Jun 12, 2017: Consumer Research Drives New Packaging Updates for Colace and Senokot Occasional Constipation Relief Products 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Purdue Pharma LP, Pharmaceuticals & Healthcare, Key Facts 2
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Purdue Pharma LP, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Purdue Pharma LP, Deals By Therapy Area, 2012 to YTD 2018 9
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Purdue Pharma Acquires Rights to VM-902A from VM Pharma 12
Kolltan Pharma Raises US$60 Million In Series D Financing 13
Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 15
University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 16
University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 17
Purdue Pharma to Form Joint Venture with AnaBios 18
Eisai Enters into Agreement with Purdue Pharma 19
Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 20
ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 21
Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 22
Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 23
Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 24
Purdue Pharma Enters into Licensing Agreement with Exicure 25
Purdue Pharma Enters into Licensing agreement with AnaBios 26
Purdue Pharma Enters Into Licensing Agreement With Medical Developments 27
Helsinn Signs Licensing Agreement with Purdue Pharma Canada 28
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 29
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 30
Purdue Pharma LP, Key Competitors 31
Purdue Pharma LP, Key Employees 32
Purdue Pharma LP, Other Locations 33
Purdue Pharma LP, Subsidiaries 33

List of Figures
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Purdue Pharma LP:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SHL TeleMedicine Ltd (SHLTN):企業の財務・戦略的SWOT分析
    SHL TeleMedicine Ltd (SHLTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • F-Secure Oyj (FSC1V):企業の財務・戦略的SWOT分析
    F-Secure Oyj (FSC1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sun Life Financial Inc:企業のM&A・事業提携・投資動向
    Sun Life Financial Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sun Life Financial Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Coherent Inc (COHR):企業の財務・戦略的SWOT分析
    Coherent Inc (COHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • BioMedomics Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioMedomics Inc (BioMedomics) is a point-of-care diagnostics company that develops and markets immunologically-based disease-specific tests and advanced highly sensitive quantitative platforms. The company provides technologies such as time-resolved lateral flow immunoassay and nanotube base …
  • Ocean Capital Limited:企業の戦略・SWOT・財務分析
    Ocean Capital Limited - Strategy, SWOT and Corporate Finance Report Summary Ocean Capital Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Jouve SA:企業の戦略的SWOT分析
    Jouve SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • XERIS Pharmaceuticals Inc (XERS):製薬・医療:M&Aディール及び事業提携情報
    Summary XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of ultra concentr …
  • NICO Life Insurance Co Ltd:企業の戦略的SWOT分析
    NICO Life Insurance Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • MPI Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary MPI Research Inc (MPI) is a contract research company that provides preclinical and early clinical research services. The company’s services comprise drug safety services, discovery sciences solutions, bioanalytical and analytical solutions, surgical services, medical device evaluation, tran …
  • hVIVO Plc (HVO):企業の財務・戦略的SWOT分析
    Summary hVIVO Plc (hVIVO), formerly Retroscreen Virology Ltd is a biopharma company that develops human-based analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human di …
  • Red Hill Iron Limited:企業の戦略・SWOT・財務分析
    Red Hill Iron Limited - Strategy, SWOT and Corporate Finance Report Summary Red Hill Iron Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nuevolution AB (NUE):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuevolution AB (Nuevolution) is a biopharmaceutical company focused on developing drug treatments for cancer and chronic inflammatory diseases. The company’s pipeline products include RORyt inhibitor, BRD (BD1), cytokine X, RORyt agonist, and GRP78. Its products are used for various indicati …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG, BAY 1905254, COM902 and TIGIT; and CGEN-XXXX/Myeloid and autoimmune diseases …
  • Ovintiv Canada ULC:企業の戦略的SWOT分析
    Ovintiv Canada ULC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Elbit Systems Ltd:戦略・SWOT・企業財務分析
    Elbit Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary Elbit Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • WH Ireland Group Plc (WHI):企業の財務・戦略的SWOT分析
    WH Ireland Group Plc (WHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • RWE AG (RWE)-石油・ガス分野:企業M&A・提携分析
    Summary RWE AG (RWE) is an energy company that generates, transmits and distributes electricity. The company generates electricity using various sources such as gas, hard coal, lignite, nuclear, hydro, biomass and renewables. It also produces oil, gas and lignite; and distributes and supplies gas. T …
  • GE Healthcare LLC-製薬・医療分野:企業M&A・提携分析
    Summary GE Healthcare LLC (GE Healthcare) a business unit of General Electric Company, is a global medical device provider that designs, develops, manufactures, and distributes diagnostic imaging and clinical systems; products and services for drug discovery, biopharmaceutical manufacturing and cell …
  • Bandera Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Bandera Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆